Using a multiplexed, reporter gene-based, highthroughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido-[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure−activity relationship studies on the carboxamide moiety led to the identification of analogues that induce chemokines and cytokines in a TLR2-dependent manner. These results represent new leads for the development of vaccine adjuvants.